3-hydroxypregnan-3-one 3-sulfate: RN given refers to (3beta,5alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3080643 |
| SCHEMBL ID | 4198024 |
| MeSH ID | M0071884 |
| Synonym |
|---|
| hpos |
| [(3s,5s,8r,9s,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate |
| 7730-00-9 |
| 3-hydroxypregnan-3-one 3-sulfate |
| 3beta-hydroxy-5 alpha-pregnan-20-one 3-sulfate |
| a39ry7z3wg , |
| pregnan-20-one, 3-(sulfooxy)-, (3beta,5alpha)- |
| 3alpha-hydroxy-5alpha-pregnan-20-one sulfate |
| unii-a39ry7z3wg |
| 3beta-hydroxy-5alpha-pregnan-20-one 3-sulfate |
| SCHEMBL4198024 |
| 3.beta.-hydroxy-5.alpha.-dihydroprogesterone sulfate |
| 3.beta.-hydroxy-5.alpha.-pregnan-20-one monosulfate |
| (3.beta.,5.alpha.)-3-(sulfooxy)pregnan-20-one |
| ba 2782 |
| pregnan-20-one, 3-(sulfooxy)-, (3.beta.,5.alpha.)- |
| 3.beta.-hydroxy-5.alpha.-pregnan-20-one sulfate |
| brexanolone metabolite m138 |
| 5.alpha.-pregnane-3.beta.-yl-20-one, sulfate |
| 20-oxopregnan-3-yl hydrogen sulfate |
| DTXSID30998547 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The modulatory effects of PS, but not 3alpha5betaS, on dose-response curves for NMDA, glutamate, and glycine are consistent with a two-state model in which PS either stabilizes or destabilizes the active state of the receptor, depending upon which NR2 subunit is present." | ( Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Farb, DH; Gibbs, TT; Malayev, A, 2002) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.16) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||